The clinical trial was sponsored by Globe Biotech Ltd. The trial was monitored by Directorate General of Drug Administration, Bangladesh. It is now commercialized in Bangladesh as GBpoietin and is indicated for chronic kidney disease in patients on dialysis and not on dialysis, in HIV-infected patients on Zidovudine, to counter effects of  concomitant myelosuppressive chemotherapy, to reduce allogeneic RBC transfusions in patients undergoing elective, noncardiac, nonvascular surgery and prevention of anemia of premature infants.